

# Selecting the right method for the right problem

---

Hugo Pedder

University of Bristol, ConnectHEOR

[bristol.ac.uk](http://bristol.ac.uk)



# Disclaimers

## Roles

- An employee of the University of Bristol
- An employee of ConnectHEOR
- A member of NICE TAC A

The views here are my own and do not represent any of the organisations I work for / with

[bristol.ac.uk](http://bristol.ac.uk)

# Overview

- A maze of indirect comparisons
- Population adjustment – why bother?
- The importance of a target population
- Approach to select an appropriate ITC method
- Where do we go from here?

“The trial populations aren’t the same”


“Poor covariate overlap”

“Multiple comparators”

“Common comparator isn’t the same”

“All important prognostic factors aren’t available”

bristol.ac.uk



# The Problem







The Perfect Method doesn't exist  
(given the data available to us)

- Fundamentally a limitation of the data
  - Not all effect modifiers / prognostic factors are balanced (populations differ between trials)
  - We don't have access to all the IPD
- We must focus on weighing up the plausibility of different assumptions



# What's the deal with population adjustment?

- Trial populations may differ
  - Imbalance in effect modifiers (anchored & unanchored ITCs)
  - Imbalance in prognostic factors (unanchored ITCs\*)
- Manufacturers typically only have access to IPD from their own trial
  - This limits the populations we can adjust into



# The Importance of the Target Population

- This is not just an issue for ITCs with  $>1$  comparator
  - What about if the target population differs to the comparator trial?



ML-NMR allows some flexibility here via Shared Effect Modifier assumption


If the pivotal trial is generalisable, then adjusting it to match another population will mean that **it cannot still be generalisable**.

For comparative treatment effects, the generalisability **of the comparator trial** should be the focus within the appraisal


# Approach for Selecting (and justifying) an ITC Method







# Choosing a PAIC Method



# Where do we go from here?

- We want your input!
  - The decision diagram is just our perspective so far
  - We want to refine it to incorporate various stakeholders
- ISPOR Task Force on PAICs?
  - ISPOR Task Force on ITC in 2014



**Thanks for listening!**

bristol.ac.uk

# Q&A Time!

## Key messages

- 1 Clear frameworks to support appropriate ITC model selection and justification
- 2 Transparent communication of complex analyses for informed decision-making
- 3 Harmonised standards across stakeholders to ensure consistency and promote innovation

Let's collaborate to navigate these challenges.